di-desmethylsibutramine

Known as: (R)-DDMS, didesmethylsibutramine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2016
012320002016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
For consumers who want to lose weight, using a product claiming to make that weight loss easier may be an attractive option… (More)
  • figure 1
Is this relevant?
2014
2014
Because of the rapid growth in dietary supplement availability and public concern for weight control, the investigation of foods… (More)
Is this relevant?
2014
2014
Herbal food supplements claiming to reduce weight may contain active pharmacological ingredients (APIs) that can be used for the… (More)
Is this relevant?
2012
2012
The presence on the market of illegal products for slimming purposes or the treatment of overweight is a public health issue… (More)
  • table 1
  • table 3
  • figure 1
  • figure 2
  • figure 2
Is this relevant?
Review
2012
Review
2012
Ion mobility spectrometry (IMS) served as a rapid, qualitative screening tool for the analysis of adulterated weight-loss… (More)
Is this relevant?
2012
2012
The partial conversion of methanol (MeOH) to formaldehyde (HCHO) in the gas chromatograph (GC) injection port was studied. The… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2011
2011
Sibutramine is a pharmacologic intervention for the treatment of obesity. The effect of CYP2B6 genotypes on the pharmacokinetics… (More)
Is this relevant?
2010
2010
Racemic sibutramine is widely used to treat obesity owing to its inhibition of serotonin and noradrenaline reuptake in synapses… (More)
Is this relevant?
2004
2004
BACKGROUND Sibutramine is an orally administered, centrally acting antiobesity drug. Sibutramine hydrochloride monohydrate is the… (More)
Is this relevant?
2000
2000
The anti-obesity agent, racemic (RS)-sibutramine, has two active metabolites, desmethylsibutramine and didesmethylsibutramine. To… (More)
Is this relevant?